Addus HomeCare Corporation ADUS R2K

Healthcare · Medical Care Facilities · United States

https://www.addus.com

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. Its Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. Its Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company serves federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is based in Frisco, Texas.

Market & Price

Market Cap

$1.71B

Current Price

$91.68

High / Low (52W)

$122.75 / $90.98

Beta

0.92

Valuation

Stock P/E

16.92

Industry PE

23.65

Forward P/E

12.27

PEG Ratio

0.90

Book Value

$61.05

Price to Book

1.50

P/S

1.18

EV/EBITDA

10.71

Dividend Yield

Profitability & Returns

ROCE

10.95%

ROE

9.45%

ROA

6.30%

Profit Margin

6.89%

Op Margin

9.37%

EPS (Latest Qtr)

$1.34

EPS (TTM)

$5.42

Balance Sheet & Liquidity

Debt/Equity

0.12

Quick Ratio

1.68

Current Ratio

1.83

Debt

$138.74M

Total Assets

$1.44B

Current Assets

$269.49M

Working Capital

$120.00M

Ownership

Promoter Holding

2.76%

Chg in Prom Hold

FII / Inst Holding

106.93%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$1.71B

Total Revenue (TTM)

$1.45B

EBITDA

$159.87M

Free Cash Flow

$102.89M

Operating Cash Flow

$144.92M

Shares Outstanding

18.66M

Gross Margin

32.45%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

14.36%

Profit 5Y

27.73%

Revenue (YoY)

7.70%

Earnings (YoY)

17.20%

PROS

Compounding revenue at 14.4% over 5 years.
Profit CAGR of 27.7% over 5 years.
Generates positive free cash flow.

CONS

Trading 25.3% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ADUS Addus HomeCare Corporation R2K	91.68	16.92	$1.71B	-	10.95%	9.45%	14.36%	27.73%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	101.67M	103.63M	108.66M	112.03M	109.13M	130.89M	137.34M	139.29M	138.51M	148.91M	168.99M	192.38M	190.22M	184.58M	193.99M	196.00M	205.30M	217.89M	216.66M	226.63M	236.94M	240.50M	251.60M	259.98M	270.72M	280.75M	286.92M	289.79M	337.71M	349.44M	362.30M	373.08M	363.61M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	230.03M	235.57M	245.59M	249.47M	247.74M
Gross Profit	23.68M	23.52M	22.19M	24.32M	25.70M	27.42M	28.66M	27.39M	28.58M	29.12M	30.79M	27.58M	35.38M	36.41M	37.43M	36.83M	39.69M	45.18M	57.54M	55.84M	55.00M	56.30M	59.10M	61.20M	68.81M	67.05M	70.19M	75.60M	75.19M	78.42M	82.32M	86.73M	88.18M	93.16M	92.20M	107.68M	113.88M	116.72M	123.61M	115.87M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	77.16M	80.99M	83.78M	81.33M	81.80M
Operating Income	5.10M	4.28M	3.02M	653.00K	4.39M	2.50M	7.69M	7.03M	5.99M	5.88M	7.47M	4.24M	6.55M	5.61M	6.43M	5.50M	7.39M	7.33M	14.53M	10.66M	9.61M	12.52M	11.72M	12.17M	17.05M	17.36M	13.51M	16.89M	17.52M	18.61M	21.54M	22.84M	23.64M	26.18M	25.95M	30.51M	32.89M	32.94M	42.28M	34.07M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	34.96M	37.38M	38.10M	47.02M	38.61M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.02M	3.52M	3.34M	2.73M	2.15M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	27.00M	29.95M	30.35M	40.15M	32.43M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.77M	7.89M	7.51M	10.37M	7.36M
Net Income	3.25M	2.89M	3.32M	157.00K	2.60M	1.70M	7.57M	4.31M	2.76M	3.46M	3.15M	4.63M	4.05M	3.36M	4.39M	4.30M	5.29M	4.91M	10.74M	8.66M	6.91M	9.12M	8.45M	8.89M	11.60M	11.58M	8.47M	11.25M	11.54M	12.68M	14.85M	15.41M	15.83M	18.08M	20.16M	21.23M	22.05M	22.85M	29.78M	25.07M
Diluted EPS	0.29	0.26	0.29	0.01	0.23	0.15	0.66	0.37	0.24	0.29	0.27	0.40	0.34	0.27	0.33	0.32	0.39	0.35	0.68	0.54	0.43	0.57	0.53	0.55	0.72	0.72	0.53	0.70	0.71	0.78	0.91	0.95	0.97	1.10	1.10	1.15	1.20	1.24	1.61	1.34

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	400.93M	425.99M	516.65M	648.79M	764.77M	-	951.12M	1.06B	1.15B	1.42B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	651.38M	718.77M	779.58M	960.66M
Gross Profit	76.61M	59.72M	61.47M	64.05M	67.74M	83.73M	91.32M	106.34M	115.88M	136.80M	179.24M	226.24M	-	299.74M	339.88M	375.02M	461.87M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	231.00M	248.92M	272.33M	323.26M
Operating Income	11.78M	9.27M	12.92M	15.66M	15.46M	18.07M	16.02M	15.48M	25.25M	22.83M	34.75M	44.51M	-	68.74M	90.96M	102.69M	138.62M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	83.14M	106.56M	120.61M	157.47M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	8.91M	11.11M	7.73M	13.61M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	60.17M	81.33M	99.35M	127.44M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	14.15M	18.81M	25.75M	31.54M
Net Income	3.60M	6.03M	-1.98M	7.63M	19.14M	12.24M	11.62M	12.16M	11.95M	16.43M	25.24M	33.13M	-	46.02M	62.52M	73.60M	95.91M
Diluted EPS	-	-	-0.18	0.71	1.73	1.10	1.04	1.07	1.03	1.33	1.77	2.08	2.81	2.84	3.83	4.06	-

Compounded Sales Growth

5 Years:	14.36%
1 Year:	7.70%

Compounded Profit Growth

5 Years:	27.73%
1 Year:	17.20%

Stock Price Performance

1 Year:	-17.34%
6 Months:	-23.91%
3 Months:	-11.45%
1 Month:	-5.45%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	166.92M	154.69M	149.86M	163.93M	180.80M	185.80M	229.86M	271.69M	348.09M	636.75M	892.58M	-	937.99M	1.02B	1.41B	1.44B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	222.81M	200.00M	260.38M	269.49M
Cash & Equivalents	6.11M	518.00K	816.00K	2.02M	1.74M	15.56M	13.36M	4.10M	8.01M	53.75M	70.41M	111.71M	145.08M	-	79.96M	64.79M	98.91M	81.62M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	125.50M	115.50M	122.88M	151.69M
Total Liabilities	-	-	78.83M	68.25M	55.44M	50.08M	52.85M	44.07M	72.10M	95.38M	79.60M	161.16M	373.91M	-	304.45M	317.73M	442.14M	352.00M
Current Liabilities	-	-	37.13M	43.29M	39.19M	45.54M	43.20M	42.19M	49.62M	55.08M	61.50M	87.53M	143.90M	-	131.15M	145.12M	155.87M	149.49M
Long Term Debt	-	-	40.03M	24.96M	16.25M	-	-	1.88M	22.48M	39.86M	17.22M	59.16M	193.90M	-	131.77M	124.13M	218.44M	120.96M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	178.05M	175.18M	273.13M	171.36M
Total Equity	-	-	88.09M	86.44M	94.42M	113.86M	126.79M	141.58M	154.67M	170.34M	268.49M	475.59M	518.68M	-	633.54M	706.69M	970.49M	1.09B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16.13M	16.23M	18.15M	18.52M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-8.93M	10.70M	15.95M	15.40M	27.39M	-	4.11M	-743.00K	52.77M	33.20M	12.02M	109.41M	-	105.11M	112.25M	116.43M	111.51M
Investing Cash Flow	-14.85M	-6.20M	-1.05M	-619.00K	2.89M	-	-10.72M	-21.74M	-24.27M	-67.79M	-188.70M	-214.24M	-	-106.59M	-119.24M	-354.61M	-32.50M
Financing Cash Flow	18.18M	-4.21M	-13.69M	-15.07M	-16.46M	-	-2.64M	26.39M	17.24M	51.24M	217.99M	138.19M	-	-87.45M	-8.18M	272.30M	-96.30M
Capital Expenditure	-671.00K	-612.00K	-551.00K	-1.11M	-887.00K	-5.27M	-2.21M	-1.71M	-3.62M	-5.35M	-4.62M	-6.83M	-	-8.30M	-9.45M	-6.05M	-7.72M
Free Cash Flow	-9.60M	10.09M	15.40M	14.29M	26.51M	-	1.89M	-2.46M	49.16M	27.85M	7.40M	102.58M	-	96.81M	102.79M	110.38M	103.79M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-88.93M	-15.17M	34.12M	-17.29M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	26.5%	27.2%	26.5%	27.6%	29.6%	-	31.5%	32.1%	32.5%	32.5%
Operating Margin %	-	-	-	-	-	-	-	3.9%	5.9%	4.4%	5.4%	5.8%	-	7.2%	8.6%	8.9%	9.7%
Net Margin %	-	-	-	-	-	-	-	3.0%	2.8%	3.2%	3.9%	4.3%	-	4.8%	5.9%	6.4%	6.7%
ROE %	-	6.8%	-2.3%	8.1%	16.8%	9.7%	8.2%	7.9%	7.0%	6.1%	5.3%	6.4%	-	7.3%	8.8%	7.6%	8.8%
ROCE %	-	7.1%	11.6%	14.2%	13.1%	13.1%	11.2%	8.6%	11.7%	8.0%	6.3%	5.9%	-	8.5%	10.3%	8.2%	10.8%

Shareholding Pattern

Insiders

2.76%

Institutions

106.93%

Public Float

109.97%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	16.56%	3.09M	$283.31M
2	Capital Research Global Investors	8.23%	1.54M	$140.76M
3	Wasatch Advisors LP	4.65%	867.83K	$79.56M
4	Vanguard Capital Management LLC	4.20%	784.41K	$71.91M
5	Dimensional Fund Advisors LP	3.99%	744.13K	$68.22M
6	Silvercrest Asset Management Group, LLC	3.91%	729.20K	$66.85M
7	State Street Corporation	3.86%	721.25K	$66.12M
8	Geode Capital Management, LLC	2.58%	481.53K	$44.15M
9	Morgan Stanley	2.41%	448.91K	$41.16M
10	Principal Financial Group, Inc.	2.33%	434.47K	$39.83M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ADUS

No recent headlines available.

ADUS · Healthcare